A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Initiation of Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Budget Impact Analysis
2021
Canadian Journal of Health Technologies
There is variation across Canadian jurisdictions in time to the initiation of biologic disease-modifying antirheumatic drug (bDMARD) therapy among adults with rheumatoid arthritis. From a pan-Canadian perspective, harmonizing time to bDMARD initiation across jurisdictions may result in savings to publicly funded drug plans in some jurisdictions but increased drug expenditures in others. The extent of savings or increased costs is dependent on jurisdiction, the number of new bDMARD users, and
doi:10.51731/cjht.2021.98
fatcat:vszq2arcfba5tkakqtze6pvjfm